Natco Pharma

What does Natco Pharma do?

Natco Pharma Ltd. is a mid-cap pharmaceutical company focused on developing and manufacturing pharmaceutical products, with recent quarterly net sales of ₹1,221 Cr and a net profit of ₹407 Cr. The company has a market cap of ₹15,407 Cr and key metrics include a P/E ratio of 8.00 and a return on equity of 24.79%.

Overview:<BR>Natco Pharma Ltd. is a mid-cap company operating in the Pharmaceuticals & Biotechnology industry, focusing on the development and manufacturing of pharmaceutical products.<BR><BR>History:<BR>Natco Pharma Limited was originally incorporated in 1981 as Natco Fine Pharmaceuticals Private Limited. It became a deemed public company in 1992 and changed its name to Natco Pharma Limited in 1993. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,221 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 407 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 15,407 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 8.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.69%<BR>- Debt Equity: -0.29<BR>- Return on Equity: 24.79%<BR>- Price to Book: 2.03<BR><BR>Contact Details:<BR>Address: Natco House, Road No 2 Banjara Hills Hyderabad Telangana : 500033<BR>Tel: 91-040-23547532<BR>Email: investors@natcopharma.co.in<BR>Website: http://www.natcopharma.co.in

Who are in the management team of Natco Pharma?

As of March 2023, the management team of Natco Pharma includes V C Nannapaneni (Managing Director), G S Murthy (Chairman), Rajeev Nannapaneni (CEO), and several other directors and executives responsible for the company's strategic direction and operations.

As of March 2023, the management team of Natco Pharma includes the following key individuals:<BR><BR>1. V C Nannapaneni - Managing Director<BR>2. G S Murthy - Chairman & Independent Director<BR>3. Rajeev Nannapaneni - Director & Chief Executive Officer<BR>4. T V Rao - Non-Executive & Independent Director<BR>5. D G Prasad - Non-Executive & Independent Director<BR>6. Leelaa Digumarti - Non-Executive & Independent Director<BR>7. PSRK Prasad - Vice President & Director<BR>8. MUR Naidu - Non-Executive & Independent Director<BR>9. D Linga Rao - President & Director<BR>10. Pavan Bhat - Vice President & Director<BR>11. Venkat Ramesh - Company Secretary & Compliance Officer<BR><BR>This diverse team is responsible for overseeing the strategic direction and operations of the company.

Who are the peers of the Natco Pharma?

Natco Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Blue Jet Health, Sai Life, Neuland Labs, Sanofi India, and Granules India. In terms of performance, Divi's Lab leads with a 1-year return of 51.69%, while Natco Pharma has a return of -13.51%.

Peers: The peers of Natco Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Blue Jet Health, Sai Life, Neuland Labs., Sanofi India, and Granules India.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Blue Jet Health, Neuland Labs., and Granules India, while Good management risk is found at Divi's Lab., Torrent Pharma, and Sai Life. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good growth is noted for Natco Pharma and Sai Life. Below Average growth is seen at Divi's Lab., Torrent Pharma, Blue Jet Health, and the rest. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Blue Jet Health, Neuland Labs., and Sanofi India, while Good capital structure is found at Torrent Pharma and Sai Life, and Average at Granules India.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while Natco Pharma has a 1-year return of -13.51%, indicating a significantly lower performance compared to its peers. The peer with the lowest 1-year return is Sanofi India at -28.96%. Additionally, the six-month return is negative for Natco Pharma, Torrent Pharma, Neuland Labs., and Sanofi India.

Who are the top shareholders of the Natco Pharma?

The top shareholders of Natco Pharma include promoter V C Nannapaneni with 15.66%, 54 mutual fund schemes holding 1.85%, and 292 foreign institutional investors (FIIs) with 17.49%. Individual investors own 23.68%, while the highest public shareholder is Belgrave Investment Fund at 2.31%, with no pledged promoter holdings.

The top shareholders of Natco Pharma include the promoters, with V C Nannapaneni being the individual with the highest holding at 15.66%. The company has a diverse shareholder base, with 54 mutual fund schemes collectively holding 1.85% and 292 foreign institutional investors (FIIs) holding 17.49%. Additionally, individual investors own 23.68% of the shares, and the highest public shareholder is Belgrave Investment Fund, which holds 2.31%. Overall, the majority of the shares are held by promoters, and there are no pledged promoter holdings.

How big is Natco Pharma?

As of 24th July, Natco Pharma Ltd. has a market capitalization of 18,196.00 Cr, with recent net sales of 4,429.50 Cr and net profit of 1,885.40 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Natco Pharma Ltd. has a market capitalization of 18,196.00 Cr, categorizing it as a Mid Cap company. <BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 4,429.50 Cr, while the sum of Net Profit for the same period is 1,885.40 Cr. <BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 5,853.10 Cr and Total Assets valued at 6,886.90 Cr.

How has been the historical performance of Natco Pharma?

Natco Pharma has shown significant financial growth from March 2020 to March 2025, with net sales increasing from INR 1,915 crore to INR 4,429.50 crore, and profit after tax rising from INR 458.10 crore to INR 1,883.40 crore, reflecting improved operational efficiency and enhanced shareholder value. Total assets also grew from INR 4,587.80 crore to INR 8,580.70 crore during this period.

Answer:<BR>The historical performance of Natco Pharma shows significant growth in various financial metrics over the years.<BR><BR>Breakdown:<BR>Natco Pharma's net sales have steadily increased from INR 1,915.00 crore in March 2020 to INR 4,429.50 crore in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from INR 1,915.00 crore in March 2020 to INR 4,429.50 crore in March 2025. The company's operating profit (PBDIT) also saw substantial growth, climbing from INR 690.00 crore in March 2020 to INR 2,550.50 crore in March 2025, indicating improved operational efficiency. Profit before tax surged from INR 568.70 crore in March 2020 to INR 2,291.40 crore in March 2025, while profit after tax increased from INR 458.10 crore to INR 1,883.40 crore during the same period. The earnings per share (EPS) rose dramatically from INR 25.32 in March 2020 to INR 105.33 in March 2025, showcasing enhanced shareholder value. On the balance sheet, total assets grew from INR 4,587.80 crore in March 2020 to INR 8,580.70 crore in March 2025, with total liabilities increasing from INR 4,587.80 crore to INR 8,580.70 crore as well. Cash flow from operating activities improved significantly, reaching INR 1,696.00 crore in March 2025, compared to INR 417.00 crore in March 2020. Overall, Natco Pharma has demonstrated robust financial growth and operational performance over the years.

Is Natco Pharma overvalued or undervalued?

As of November 17, 2025, Natco Pharma is considered an attractive investment opportunity, trading at a PE ratio of 9.55 and showing potential for growth with favorable valuation metrics compared to peers, despite recent underperformance against the Sensex.

As of 17 November 2025, Natco Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.55, an EV to EBIT of 7.93, and a ROCE of 25.97%. These ratios suggest that Natco Pharma is trading at a discount compared to its peers, particularly when compared to Sun Pharma, which has a PE ratio of 36.69, and Divi's Lab, with a PE ratio of 69.78.<BR><BR>In the context of its peer group, Natco Pharma's valuation metrics stand out as more favorable, especially with a PEG ratio of 0.00, indicating potential for growth without the corresponding high valuation. While the stock has underperformed the Sensex over the past year, it has shown resilience with a 3-year return of 43.82%, suggesting that it may be positioned for recovery. Overall, Natco Pharma appears to be a compelling investment opportunity within the pharmaceuticals and biotechnology sector.

Is Natco Pharma technically bullish or bearish?

As of December 3, 2025, Natco Pharma's trend is sideways with mixed signals: weekly indicators suggest mild bullishness while monthly indicators are bearish, indicating a lack of strong momentum.

As of 3 December 2025, the technical trend for Natco Pharma has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD and KST indicate a mildly bullish outlook, while the monthly MACD and KST are bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands are bullish weekly but mildly bearish monthly. Daily moving averages are mildly bearish. Overall, the indicators suggest a lack of strong momentum in either direction, reflecting the sideways trend.

Has Natco Pharma Ltd. declared dividend?

Yes, Natco Pharma Ltd. has declared a dividend of 75% (₹1.5 per share) with an ex-date of February 18, 2026. While the company shows a strong total return of 57.75% over three years, shorter-term returns have been negative.

Natco Pharma Ltd. has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 75%<BR>- Amount per share: 1.5<BR>- Ex-date: 18 Feb 26<BR><BR>Dividend Yield: 0.6%<BR><BR>Total Returns by Period:<BR>Over the 3-month period, the price return was -0.48%, the dividend return was 0.37%, resulting in a total return of -0.11%.<BR><BR>In the 6-month period, the price return was -9.07%, the dividend return was 0.57%, leading to a total return of -8.5%.<BR><BR>For the 1-year period, the price return was -15.54%, the dividend return was 0.60%, culminating in a total return of -14.94%.<BR><BR>During the 2-year period, the price return was -4.11%, the dividend return was 1.19%, resulting in a total return of -2.92%.<BR><BR>In the 3-year period, the price return was 53.95%, the dividend return was 3.80%, leading to a total return of 57.75%.<BR><BR>For the 4-year period, the price return was -10.84%, the dividend return was 3.07%, culminating in a total return of -7.77%.<BR><BR>In the 5-year period, the price return was -3.79%, the dividend return was 3.69%, resulting in a total return of -0.1%.<BR><BR>Overall, while Natco Pharma Ltd. has declared a substantial dividend, the total returns over various periods show a mixed performance, with significant negative returns in the shorter terms but a strong positive return over the longer three-year period.

When is the next results date for Natco Pharma Ltd.?

The next results date for Natco Pharma Ltd. is 29 May 2026.

The next results date for Natco Pharma Ltd. is scheduled for 29 May 2026.

Why is Natco Pharma Ltd. falling/rising?

As of 29-May, Natco Pharma Ltd. is facing a significant stock price decline to 1,016.75, down 13.51%. Despite a year-to-date increase, recent volatility and a profit decline indicate a troubling short-term outlook.

As of 29-May, Natco Pharma Ltd. is experiencing a significant decline in its stock price, currently at 1,016.75, which reflects a change of -158.85 or -13.51%. The stock has underperformed its sector by -12.02% today and has been on a downward trend, losing value for the last two days with a total decline of -14.34% during this period. <BR><BR>The stock's performance over the past week shows a decrease of -13.12%, while it has also fallen -7.04% over the past month. Despite a year-to-date increase of +12.53%, the recent volatility and negative returns indicate a troubling short-term outlook. The stock has traded within a wide range today, reaching a high of Rs 1200 but dropping to a low of Rs 1001.05, showcasing high volatility with an intraday volatility of 11.52%.<BR><BR>Additionally, there has been a decline in investor participation, with delivery volume falling by -3.55% compared to the five-day average. This decrease in trading activity may contribute to the downward pressure on the stock price. Although the company maintains a strong management efficiency and is net-debt free, the recent profit decline of -16.5% over the past year suggests underlying challenges that may be affecting investor sentiment and stock performance.

Should I buy, sell or hold Natco Pharma Ltd.?

Which are the latest news on Natco Pharma?

Are Natco Pharma Ltd. latest results good or bad?

Natco Pharma Ltd.'s latest Q4 FY26 results show a net profit increase of 76.83% quarter-on-quarter, but a 34.11% decline year-on-year, alongside a concerning 39.47% drop in net sales compared to last year. Overall, while there are some positive quarterly trends, the company faces significant operational challenges and declining margins.

Natco Pharma Ltd.'s latest results for Q4 FY26 present a mixed picture. On one hand, the company reported a net profit of ₹267.90 crores, which is a significant increase of 76.83% quarter-on-quarter. However, this figure is down 34.11% year-on-year, indicating a decline compared to the same quarter last year. <BR><BR>Net sales also showed a sequential improvement of 14.18% from the previous quarter, reaching ₹739.10 crores. Yet, this represents a concerning year-on-year decline of 39.47%, which raises red flags about the company's operational health. <BR><BR>Moreover, the operating margin has dropped to 17.26%, marking a multi-quarter low and reflecting significant margin compression. The company's reliance on a tax reversal of ₹89.20 crores to boost profits further complicates the outlook, as it obscures the underlying operational weaknesses.<BR><BR>In summary, while there are some positive signs in terms of quarterly growth, the overall performance indicates significant challenges, particularly with revenue contraction and declining margins. Investors may view this as a cautious signal, suggesting that the company is facing substantial operational headwinds despite some short-term gains.